Susana Rubio-Mediavilla

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

Laura Ochoa‐Callejero, Laura Pérez‐Martínez, Susana Rubio-Mediavilla et al. · PLoS ONE · 2013 · 89 citations · Full text

Liver Fibrosis, Immunology, Pathology +17

Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

Laura Pérez‐Martínez, Patricia Pérez‐Matute, Javier Aguilera‐Lizarraga et al. · Journal of Antimicrobial Chemotherapy · 2014 · 76 citations

Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer

Laura Ochoa‐Callejero, Josune Garcı́a-Sanmartı́n, Sonia Martínez-Herrero et al. · Scientific Reports · 2017 · 20 citations · Full text

Intravascular large B cell lymphoma

Ricardo Garcı́a-Muñoz, Susana Rubio-Mediavilla, Diego Robles de Castro et al. · Leukemia Research Reports · 2014 · 18 citations · Full text

Lymphoid Neoplasia, Lymphoma Cells, Surgical Pathology +9

Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet

Laura Pérez‐Martínez, Laura Ochoa‐Callejero, Susana Rubio-Mediavilla et al. · Translational research · 2018 · 16 citations

High-fat Diet, Fatty Liver Disease, Inflammation +16